Bristows advises Oxford Science Enterprises on $90m Series A investment in Alethio Therapeutics
16.11.2026
Bristows has advised Oxford Science Enterprises (OSE) on its participation in a $90 million (£67 million) oversubscribed Series A financing for Alethio Therapeutics, an Oxford spin-out developing a new generation of therapies for myeloproliferative neoplasms (MPNs).
The financing was co-led by Sofinnova Partners and RA Capital alongside founding investor OSE, with further backing from Cancer Research Horizons and the University of Oxford, bringing together a transatlantic syndicate of life sciences investors.
The funding will support Alethio’s transition into a clinical-stage company and the development of its pipeline of targeted therapies for MPNs, a group of chronic blood cancers. This includes progressing its lead programme, ATX-011, through Phase 1/2a studies in essential thrombocythaemia and advancing further programmes towards IND submission.
Alethio was founded as a University of Oxford spin-out by Professors Adam Mead and Beth Psaila and is developing therapies designed to target the disease-driving cells that sustain MPNs.
The Bristows team advising OSE was led by corporate partner Marek Petecki, supported by Oliver Alsop, Senior Associate.
To find out more about our venture capital and corporate expertise, see here.
For more information, please contact:
katherine.farrell@bristows.com | +44 20 7400 8000
Marek Petecki
Author
Oliver Alsop
Author